PD-1 checkpoint inhibition: Toxicities and management

Urologic Oncology: Seminars and Original Investigations

Volumn 35, Issue 12, 2017, Pages 701-707

  Hahn, Andrew W ^a   Gill, David M ^a   Agarwal, Neeraj ^a   Maughan, Benjamin L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Atezolizumab; Avelumab; Durvalumab; Immune related adverse events; Management; Nivolumab; PD 1 inhibitor; PD L1 inhibitor; Pembrolizumab; Treatment

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; CHECKPOINT KINASE INHIBITOR; DURVALUMAB; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PEMBROLIZUMAB; STEROID; CD274 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CARDIOTOXICITY; COLITIS; DRUG TOXICITY; ENDOCRINE DISEASE; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; NEPHRITIS; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DEGENERATIVE DISEASE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; COLITIS; EXANTHEMA; HEPATITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MYCOPHENOLIC ACID; NEOPLASMS; NEPHRITIS; NEURODEGENERATIVE DISEASES; PNEUMONIA; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85030833426     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2017.08.005     Document Type: Review

References (61)

1. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
2. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
3. Francisco, L.M., Sage, P.T., Sharpe, A.H., The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236 (2010), 219–242.
4. Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
5. Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
6. Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
7. Ferris, R.L., Blumenschein, G. Jr, Fayette, J., et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375 (2016), 1856–1867.
8. Ansell, S.M., Lesokhin, A.M., Borrello, I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
9. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
10. Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
11. Sharma, P., Callahan, M.K., Bono, P., et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17 (2016), 1590–1598.
12. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
13. Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
14. Rittmeyer, A., Barlesi, F., Waterkamp, D., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
15. Kaufman, H.L., Russell, J., Hamid, O., et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17 (2016), 1374–1385.
16. Massard, C., Gordon, M.S., Sharma, S., et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34 (2016), 3119–3125.
17. Maughan, B.L., Bailey, E., Gill, D.M., Agarwal, N., Incidence of immune-related adverse events with program death receptor-1 and program death receptor-1 ligand-directed therapies in genitourinary cancers. Front Oncol, 7, 2017, 56.
18. Chen, T.W., Razak, A.R., Bedard, P.L., Siu, L.L., Hansen, A.R., A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 26 (2015), 1824–1829.
19. De Velasco, G., Je, Y., Bosse, D., et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5 (2017), 312–318.
20. Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N.H., Hodi, F.S., Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2 (2016), 1607–1616.
21. Postow, M.A., Chesney, J., Pavlick, A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
22. Weber, J.S., Hodi, F.S., Wolchok, J.D., et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35 (2017), 785–792.
23. US Food and Drug Administration. Yervoy (Ipilumab) Risk Evaluation and Mitigation Strategy (REMS), 2011.
24. Friedman, C.F., Proverbs-Singh, T.A., Postow, M.A., Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2 (2016), 1346–1353.
25. Tirumani, S.H., Ramaiya, N.H., Keraliya, A., et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3 (2015), 1185–1192.
26. Postow, M.A., Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book, 2015, 76–83, 10.14694/EdBook_AM.2015.35.76 http://meetinglibrary.asco.org/record/106336/edbook#fulltext; [accessed 09.04.2017].
27. Weber, J., Thompson, J.A., Hamid, O., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15 (2009), 5591–5598.
28. Yanai, S., Nakamura, S., Matsumoto, T., Nivolumab-induced colitis treated by infliximab. Clin Gastroenterol Hepatol 15 (2017), e80–e81.
29. Weber, J.S., Kudchadkar, R.R., Yu, B., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or naive melanoma. J Clin Oncol 31 (2013), 4311–4318.
30. Spain, L., Diem, S., Larkin, J., Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44 (2016), 51–60.
31. Kim, K.W., Ramaiya, N.H., Krajewski, K.M., et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31 (2013), 1071–1077.
32. Johncilla, M., Misdraji, J., Pratt, D.S., et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 39 (2015), 1075–1084.
33. Chmiel, K.D., Suan, D., Liddle, C., et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29 (2011), e237–e240.
34. Johnson, D.B., Sullivan, R.J., Menzies, A.M., Immune checkpoint inhibitors in challenging populations. Cancer 123 (2017), 1904–1911.
35. El-Khoueiry, A.B., Sangro, B., Yau, T., et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389 (2017), 2492–2502.
36. Nishino, M., Ramaiya, N.H., Awad, M.M., et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22 (2016), 6051–6060.
37. Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
38. Naidoo, J., Wang, X., Woo, K.M., et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35 (2017), 709–717.
39. Sibaud, V., Meyer, N., Lamant, L., Vigarios, E., Mazieres, J., Delord, J.P., Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28 (2016), 254–263.
40. Joseph, R.W., Cappel, M., Goedjen, B., et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res 3 (2015), 18–22.
41. Carlos, G., Anforth, R., Chou, S., Clements, A., Fernandez-Penas, P., A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res 25 (2015), 265–268.
42. Saw, S., Lee, H.Y., Ng, Q.S., Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer 81 (2017), 237–239.
43. Belum, V.R., Benhuri, B., Postow, M.A., et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60 (2016), 12–25.
44. Hua, C., Boussemart, L., Mateus, C., et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152 (2016), 45–51.
45. Torino, F., Corsello, S.M., Salvatori, R., Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 28 (2016), 278–287.
46. Dillard, T., Yedinak, C.G., Alumkal, J., Fleseriu, M., Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13 (2010), 29–38.
47. Okamoto, M., Okamoto, M., Gotoh, K., et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diab Investig 7 (2016), 915–918.
48. Hickmott, L., De La Pena, H., Turner, H., et al. Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature. Target Oncol 12 (2017), 235–241.
49. Menzies, A.M., Johnson, D.B., Ramanujam, S., et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28 (2017), 368–376.
50. Cortazar, F.B., Marrone, K.A., Troxell, M.L., et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90 (2016), 638–647.
51. Shirali, A.C., Perazella, M.A., Gettinger, S., Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 68 (2016), 287–291.
52. Wanchoo, R., Karam, S., Uppal, N.N., et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45 (2017), 160–169.
53. Escandon, J., Peacock, S., Trabolsi, A., Thomas, D.B., Layka, A., Lutzky, J., Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J Immunother Cancer, 5, 2017, 3.
54. Zimmer, L., Goldinger, S.M., Hofmann, L., et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016), 210–225.
55. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
56. Mandel, J.J., Olar, A., Aldape, K.D., Tremont-Lukats, I.W., Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 344 (2014), 229–231.
57. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
58. Maurice, C., Schneider, R., Kiehl, T.R., et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res 3 (2015), 1299–1302.
59. Johnson, D.B., Balko, J.M., Compton, M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
60. Chauhan, A., Burkeen, G., Houranieh, J., Arnold, S., Anthony, L., Immune check point associated cardiotoxicity: case report with systematic review of literature. Ann Oncol 28 (2017), 2034–2038.
61. Heinzerling, L., Ott, P.A., Hodi, F.S., et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer, 4, 2016, 50.